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Summary Botulinum neurotoxins (BoNTs) are the most potent toxins known and the 
causative agents of the rare but potentially life-threatening disease botulism. The 
elaborate mode of action of BoNTs at the molecular level, their exquisite specific-
ity for peripheral motor neurons, and their ability to effectively inhibit neurotrans-
mitter release led to the development of BoNTs into highly valued pharmaceuti-
cal products. Both diagnostics of botulism and potency testing of pharmaceutical 
BoNT preparations still employ the mouse bioassay as “gold standard assay”. This 
animal experiment can pose a heavy burden on the animal, including a fatal 
outcome of testing. Additionally, several analytical disadvantages have been 
described. Consequently, the development of animal replacement methods is a 
long pursued goal which has been focused mainly on replacement methods for 
pharmaceutical potency testing so far. However, fundamentally different require-
ments and challenges apply for diagnostics of botulism and potency testing of 
BoNT pharmaceuticals, which necessitates the development of different assays 
tailored for each purpose. Here we review the underlying causes for this intricacy 
which are rooted in both the biological characteristics of the BoNTs as well as 
assay specific requirements. We review different functional assays that have been 
developed to replace the mouse bioassay. Despite significant progress in recent 
years, further substantial work is needed to pave the way for a fully validated 
replacement for the mouse bioassay for botulism diagnostics.
Keywords: botulinum neurotoxins, botulism, diagnostics, mouse bioassay, 
replacement methods, functional assays
Zusammenfassung Botulinum Neurotoxine (BoNTs) sind die giftigsten bekannten Substanzen und 
ursächlich für die seltene, aber lebensbedrohliche Erkrankung Botulismus. Auf-
grund ihres raffinierten molekularen Wirkmechanismus, ihrer exquisiten Spezifität 
für periphere Motorneuronen und ihrer Fähigkeit zur effektiven Blockade der 
Neurotransmitter-Ausschüttung wurden zudem auf BoNT basierende, hochwirk-
same pharmazeutische Produkte entwickelt. Sowohl in der Botulismus-Diagnostik 
als auch bei der Wirksamkeitsprüfung pharmazeutischer Präparate wird nach wie 
vor der Maus-Bioassay als „Goldstandardmethode“ verwendet. Dieser Tierversuch 
kann mit schweren Belastungen bis hin zum Tod der Tiere einhergehen. Darüber 
hinaus weist der Assay verschiedene analytische Schwächen auf. Folglich stellt die 
Entwicklung einer Tierversuchsersatzmethode ein seit langem verfolgtes Unter-
fangen dar, welches bislang hauptsächlich auf die Entwicklung von Ersatzmetho-
den für die pharmazeutische Wirksamkeitsprüfung fokussiert war. Fundamental 
unterschiedliche Anforderungen an die Botulismus-Diagnostik und die Wirksam-
keitsprüfung erfordern jedoch die Entwicklung verschiedener, zielgerichteter 
Nachweisverfahren für beide Zwecke. Der vorliegende Übersichtsartikel erläutert 
die zugrunde liegenden Ursachen, welche sowohl auf biologischen Eigenschaf-
ten der BoNTs als auch auf Assay-spezifischen Besonderheiten basieren, und 
stellt eine Übersicht verschiedener funktioneller Methoden zusammen, die zum 
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Ersatz des Maus-Bioassays entwickelt wurden. Trotz bedeutender Fortschritte in 
den letzten Jahren sind weitere umfassende Arbeiten notwendig, um zu einer 
vollständig validierten Tierversuchsersatzmethode für den Maus-Bioassay zur 
Botulismus-Diagnostik zu gelangen. 
Schlüsselwörter: Botulinum Neurotoxine, Botulismus, Diagnostik, Maus-Bioassay, 
Tierversuchsersatzmethode, Funktionelle Methoden
Botulism and the family of botulinum 
neurotoxins
Botulism is a rare but potentially life-threatening disease 
affecting both humans and animals and is caused by 
botulinum neurotoxins (BoNTs) (Johnson and Monte-
cucco 2008). The toxins are produced by anaerobic spore 
forming bacteria of the genus Clostridium (C.), namely 
C.  botulinum, C.  baratii and C.  butyricum, which occur 
ubiquitously in the environment, especially in soil or 
marine sediments (Dodds 1992, Peck 2009). Depend-
ing on the entry route, both the preformed toxins and 
clostridial spores can induce botulism, which occurs 
in three major forms (Fig.  1A): Food-borne botulism 
develops when improperly processed food is ingested, in 
which the bacteria found appropriate anaerobic growth 
conditions and produced the neurotoxins (Peck et al. 
2011). This type of botulism is mostly caused by home-
canned food (meat, fish, vegetables) containing pre-
formed neurotoxins, but commercially available food 
can also be affected (Cowden 2011, Mad’arova et al. 
2017, Mazuet et al. 2015, Peck 2006). Infant botulism can 
occur in infants under 12 months old when they ingest 
bacterial spores, which, in the absence of the competi-
tive endogenous gut flora, may germinate and colonize 
the intestinal tract and start to produce neurotoxin. For 
infant botulism, uptake of honey has been identified as 
a risk factor since honey is a natural product that might 
contain C.  botulinum spores (Grant et al. 2013, Ringe 
et al. 2014, Rosow and Strober 2015). Wound botulism 
occurs after entry of spores into deep wounds and is rare 
in the general population. However, clusters of wound 
botulism as well as sporadic cases among people who 
inject drugs have been reported in a number of Euro-
pean countries since 2000 (Akbulut et al. 2005, Alpers 
et al. 2005, Brett et al. 2005, Barry et al. 2009, Schroeter 
et al. 2009, Hope et al. 2012, MacDonald et al. 2013). In 
Germany, botulism is a notifiable disease in humans 
according to §6 and §7 of the Protection against Infec-
tion Act. Hereby a total number of 134 cases of botulism 
have been reported between 2001 and 2017, making up 
approximately 8 human cases on average per year. Of 
those, food-borne botulism represents the most frequent 
form with about 70% of all cases, followed by wound 
botulism (21%) and infant botulism (9%) (Robert Koch 
Institute 2018).
For animal botulism, numbers are not available due 
to the absence of a notification requirement for the 
veterinary disease. Animal botulism is usually caused by 
the ingestion of BoNT-containing feed, but sporadically 
cases of wound botulism may also occur (Bernard et al. 
1987). The source of contamination is most frequently 
identified as contamination of the forage with dead 
animals or carcasses (Anniballi et al. 2013b). Less com-
mon are poisonings by direct osteophagia (Seddon 1922, 
Theiler and Robinson 1927, van der Lugt et al. 1995, 
Riet-Correa et al. 2012). Animal botulism can affect 
wildlife as well as husbandry or zoo animals. In contrast 
to human botulism, outbreaks among cattle, poultry, 
mink, but also wild birds and waterfowls can occur at a 
large scale, possibly affecting hundreds or thousands of 
animals (Grüll and Rauer 2000, Lindström et al. 2004, 
Popp et al. 2012, Włodarczyk et al. 2014, Dlabola et al. 
2016, Relun et al. 2017). In Germany and Europe cattle 
and poultry farms are affected most often. More seldom 
horses or other animals are affected (Schettler 1979, 
Popp et al. 2012, Souillard et al. 2014, Souillard et al. 
2015, Woudstra et al. 2015, Dlabola et al. 2016). Accord-
ing to current information botulism in farm animals is a 
rare disease. However a high number of individuals can 
be affected in a single outbreak, i.e. 115 animals (40%) of 
a cattle herd were lost during a recent outbreak (Dlabola 
et al. 2016). Hereby, botulism outbreaks can be associ-
ated with large economical losses.
In humans, the typical symptoms of botulism are char-
acterized by flaccid descending paralysis. This paraly-
sis first affects the ocular muscles (ptosis, double and 
blurred vision), facial and neck musculature (slurred 
speech, swallowing problems, dry mouth). It eventually 
leads to muscle weakness in the peripheral upper and 
lower limbs. In severe cases, if the paralysis reaches res-
piratory muscles, it may lead to death due to ventilatory 
failure unless supportive care is provided (Dembek et al. 
2007). In animals, the symptoms observed are similar 
including weak tongue strength, sometimes protrusion 
and extensive salivation as hallmarks in cattle. Birds 
show paralysis of inner eyelids, droopy wings, weak legs, 
a floppy neck (limberneck) due to muscle weakness, and 
drowning, particularly in waterfowls (Critchley 1991, 
Dlabola et al. 2010, Anniballi et al. 2013b). 
Those symptoms are caused by the uptake of BoNT 
released by the vegetative bacteria in a complexed form 
associated with different accessory proteins (non-toxic 
non-hemagglutinin, NTNH, and for some toxin sero-
types additionally three different hemagglutinins [Lee 
et al. 2014, Lam and Jin 2015]) which protect the neu-
rotoxin from the harsh conditions of the gastrointestinal 
tract (Fig. 1B). The associated complex proteins, espe-
cially hemagglutinins, are involved in binding of the 
neurotoxin complex to the intestinal epithelial barrier 
and transcytosis through the small intestine by a yet to 
be defined molecular pathway (Lee et al. 2014, Fujinaga 
and Popoff 2017). Once in the circulation, the BoNT, now 
stripped off its complex proteins, finally reaches the neu-
romuscular junction where it exerts its biological activity 
by a highly specific mode of action (Fig. 2 A). Here, indi-
vidual domains of the 150 kDa BoNT molecule carry out 
different parts of the molecular mechanism (Rossetto et 
al. 2014). First, the 50 kDa C-terminal domain (HC) of 
the 100 kDa large heavy chain binds to specific recep-
tor molecules embedded in the presynaptic membrane 
before bound toxins are taken up into fused synaptic 
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vesicles (Rummel 2013, Rummel 2016, Pirazzini et al. 
2017). According to the current dual-receptor binding 
paradigm the interactions with a (glyco-)protein and 
the carbohydrate-groups of polysialo-gangliosides are 
needed for high affinity binding of BoNT to the pre-
synaptic membrane (Montecucco 1986, Rummel 2016). 
Different serotypes employ different protein receptors, 
either synaptic vesicle protein 2 (SV2) or synaptotagmin 
(Syt, Fig. 2 B) (Rummel 2013, Lam et al. 2015, Rum-
mel 2016). Recent work has shown that binding to the 
SV2 protein receptors is enhanced by glycosylation of 
SV2 (Mahrhold et al. 2016, Yao et al. 2016). It is likely 
that other BoNT require also glycosylation of their pro-
tein receptor for high-affinity binding. Noteworthy, both 
identified protein receptors (SV2 and Syt) are part of the 
neurotransmitter-loaded vesicles and thus only exposed 
to the cell surface during transmitter release. After bind-
ing to the receptors BoNT is internalized in endocytosed 
synaptic vesicles which are then acidified by vesicu-
lar ATPase (Pirazzini et al. 2017). Vesicle acidification 
induces integration of the 50 kDa N-terminal domain 
(HN) of the heavy chain into the endosomal membrane, 
hereby forming a pore (Colasante et al. 2013, Fischer 
2013). Finally, the enzymatically active 50 kDa light chain 
FIGURE 1: A. Sources and forms of botulism in humans. Botulism is caused by botulinum neurotoxin (BoNT) producing, anaerobic 
spore forming bacteria of the Clostridia species (C. botulinum, C. baratii, C. butyricum). Either preformed toxin or spores are inge-
sted from contaminated food (food-borne botulism), taken up orally by infants under 12 months old (infant botulism) or injected via 
contaminated drugs (wound botulism). B. Entry route of BoNTs and symptoms of botulism. BoNTs complexed with proteins media-
ting protection against low pH and protease in the stomach undergo transcytosis through the small intestine (1) and are released in 
the circulation (2) until they reach their site of action, synapses on the motor neuronal endplate (3). Here, by their specific mode of 
action (see Fig. 2) they block neurotransmitter release which leads to descending flaccid paralysis and, ultimately, death by respiratory 
failure (4).
The image of the neuron was obtained from Vecteezy.com. The image depicting ptosis as a typical symptom of botulism was taken by Herbert L. Fred, MD and Hendrik A. van Dijk and can be used 
under a creative commons licence 2.0 (http://cnx.org/content/m14960/latest/). The image of the case of infant botulism was taken by the CDC / Dr. Charles Hatheway (1977) (ID3355) and is in the 
public domain (https://phil.cdc.gov/Details.aspx?pid=1935). The image depicted under wound botulism was published (Sam and Beynon 2010). Copyright © (2017) Massachusetts Medical Society. 
Reprinted with permission from Massachusetts Medical Society. Vector graphics depicting food and animals were obtained from Shutterstock. The image used for the schematic human body was 
obtained from https://commons.wikimedia.org/wiki/Human_body_diagrams and is in the public domain.
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is transferred through this pore by a yet undetermined 
mechanism. In the cytosol, reduction of the disulfide 
bridge between light and heavy chain by the thioredoxin 
reductase/ thioredoxin system releases the light chain 
into the cytoplasm (Pirazzini et al. 2015, Pirazzini et 
al. 2016). Here, the light chain specifically cleaves pro-
teins of the soluble NSF attachment protein receptor 
(SNARE) complex which mediates fusion of acetylcho-
line filled vesicles with the presynaptic membrane via 
its Zn2+-dependent endopeptidase activity (Binz 2013). 
This leads to blockage of neurotransmitter release which 
inhibits signal transduction from peripheral nerves to 
muscle cells ultimately causing the paralytical symptoms 
of botulism.
The family of the botulinum neurotoxins comprises 
seven accepted serotypes, BoNT/A to BoNT/G. Botulism 
in humans can be caused by serotypes BoNT/A, B, E, and 
F, whereas serotypes C and D cause botulism in livestock, 
e.g. in cattle and poultry, and in wild animals (Monte-
cucco and Rasotto 2015). In case of veterinary botulism, 
mosaic serotypes of BoNT/C and D (designated BoNT/
CD and BoNT/DC) also exist which comprise the light 
chain and HN-domain of one serotype and the recep-
tor binding HC domain resembling the other serotype 
(Sakaguchi et al. 2015, Hansbauer et al. 2016). Serotype 
G has not been clearly assigned to a natural outbreak in 
humans or animals (Peck et al. 2017). Some strains of C. 
botulinum can produce two or even three different BoNTs 
(Williamson et al. 2016). Recently, a novel, putatively 8th 
serotype termed BoNT/H was proposed (Barash and 
Arnon 2014, Dover et al. 2014). A more detailed analysis 
showed that the catalytic domain of BoNT/H is highly 
homologous to the unique catalytic domain of BoNT/F5 
which is different from all other sero- and subtypes. The 
receptor binding domain of BoNT/H, however, shows 
a high degree of homology to BoNT/A. Moreover, the 
capability of BoNT/H to induce botulism can be blocked 
by antitoxins derived against BoNT/A (Maslanka et al. 
2016). Interestingly, its light chain (as well as the light 
chain of BoNT/F5) represents a novel ‘cleavotype’ which 
cleaves its SNARE protein at a unique position (Kalb et 
al. 2012b, Kalb et al. 2015b). Therefore, BoNT/H is alter-
natively referred to as BoNT/FA or HA (the latter name 
is preferred by the authors and used in this manuscript) 
(Kalb et al. 2015b, Maslanka et al. 2016, Pellett et al. 2016, 
Yao et al. 2017). BoNT/HA is potentially also pathogenic 
to humans as it originates from a strain causing infant 
botulism, although its toxicity is clouded by the fact that 
the bivalent strain also produces BoNT/B (Barash and 
Arnon 2014, Dover et al. 2014). 
Although all BoNT serotypes exert a similar mode of 
action, they differ by the receptor molecules employed for 
initial binding to the synaptic membrane. Furthermore 
the cleaved synaptic substrate as well as the individual 
cleavage site on the substrate proteins of the SNARE 
complex vary (Fig. 2B). Regarding the receptor mo lecules, 
FIGURE 2: A. Three domains of the 150 kDa proteo-
toxin mediate the mode of action of BoNTs. Receptor 
binding (1) on the presynaptic membrane is mediated 
by the 50 kDa large C-terminal domain of the 100 kDa 
heavy chain. After uptake and acidification, the 50 kDa 
N-terminal domain of the heavy chain inserts in the 
endosomal membrane, hereby forming a pore through 
which the 50 kDa light chain is translocated into the 
cytoplasm (2). Finally, the light chain cleaves different 
proteins of the SNARE complex (3) hereby inhibiting 
fusion of neurotransmitter filled synaptic vesicles with 
the presynaptic membrane, hereby blocking signal 
transduction from the peripheral neurons to the mus-
cles leading to paralysis. B. Serotype-specific receptor 
binding for pathogenic BoNT serotypes. According to 
the dual-receptor binding model (Montecucco 1986) all 
BoNT serotypes need simultaneous interaction with both 
a ganglioside and a synaptic vesicle protein (either SV2 
or Syt) for high affinity binding. However, serotype-
specific differences exist in which protein receptors are 
employed (Rummel 2013, Lam et al. 2015, Rummel 
2016). C. Cleavage sites on different substrate proteins 
for pathogenic BoNT serotypes. The BoNT serotypes 
differ in which SNARE protein (VAMP-2 or SNAP-25) 
is cleaved and the specific amino acid position targeted 
(Binz 2013).
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vital parts of the function such as receptor binding or 
substrate cleavage are not affected. If vital parts of the 
protein function are affected, the altered function truly 
reflects a different potency of the toxin variant. An exam-
ple would be the subtype BoNT/A4 which has an about 
three orders of magnitude lower toxicity compared to the 
prototypic BoNT/A1 presumably due to a less efficient 
entry into neurons (Whitemarsh et al. 2013). The concept 
of functional BoNT detection by displaying endopepti-
dase activity and/or receptor binding in vitro has been 
used as a starting point for establishing animal replace-
ment methods (see section “replacement methods for 
diagnostics of botulism”).
Besides causing botulism, BoNTs are classical dual-use 
substances: Due to their high toxicity – the LD50 is only 
1 ng per kg bodyweight in humans (Gill 1982) – early on 
efforts have been reported to make use of these potent 
toxins as biological weapons as reviewed by Arnon and 
colleagues (Arnon et al. 2001). On the other hand, their 
exquisite specificity is also harnessed in highly beneficial 
ways. BoNTs known under different trademarked brand 
names such as BOTOX®, Vistabel®, Dysport®, Azzalure®, 
Xeomin®, or Bocouture® (all BoNT/A) and Myobloc® 
(BoNT/B) are approved based on their paralyzing effects 
on muscles for the treatment of an ever increasing 
number of medical conditions ranging from strabismus, 
blepharospasmus, migraine, dystonia, spasticities, uro-
logical conditions, hyperhidrosis up to the newly evalu-
ated treatment of depression (Bigalke 2013, Pirazzini et 
al. 2017). More popular in the public, however, is their use 
in aesthetic medicine to smooth facial wrinkles. For clini-
cal use, only minute amounts of toxins are needed for the 
efficient treatment, making precise quantification of the 
biological potency a prerequisite for the safe application.
Challenges in BoNT detection
Generally, there are two different fields in BoNT research 
which require highly sensitive detection of BoNT 
mo lecules (Dorner et al. 2013):
• Potency testing of highly purified BoNT pharmaceuti-
cals approved for medical / cosmetic application
• Diagnostics of suspect cases of botulism in humans 
and animals
Both fields have quite contrary requirements for diag-
nostic approaches (Tab. 1):
First, diagnostic assays for BoNTs have to detect all 
pathogenic sero- and subtypes reliably while only two 
specific sero- and subtypes, BoNT/A1 and BoNT/B1, are 
employed in pharmaceutical products (Pirazzini et al. 
2017). Therefore, a much more comprehensive coverage 
of BoNT sero- and subtypes is needed for diagnostics 
as compared to potency testing – basically, all known 
and even the yet unknown BoNT subtypes have to be 
detected. A meaningful approach to reduce the analyti-
cal complexity is to develop separate assays for serotypes 
pathogenic to humans as compared to the serotypes 
pathogenic to animals only (Hansbauer et al. 2016), 
hereby separating serotypes A, B, E, F, and the novel 
HA from C, D, CD, and DC depending on the analyti-
cal focus. Though often practiced, it has to be taken into 
account that in rare cases serotypes usually pathogenic 
to humans can also occur in veterinary botulism (John-
son et al. 2010, Lamoureux et al. 2015).
BoNT/A, D, E, F and HA use the protein receptor SV2 
plus gangliosides for high affinity binding, whereas 
BoNT/B, DC and G bind to Syt as protein receptor. Only 
for BoNT/C no protein receptor has been identified so 
far, instead two ganglioside molecules are used for bind-
ing (Rummel 2013). With respect to enzymatic activity, 
BoNT/A, C and E cleave the synaptic protein SNAP-25 
whereas BoNT/B, D, F, G and HA target the substrate 
VAMP-2 at individual amino acid positions (Fig. 2C) 
(Binz 2013). BoNT/C additionally cleaves syntaxin as a 
second substrate (Blasi et al. 1993, Schiavo et al. 1995).
Adding further to this complexity on the molecular 
level is the fact that with the advent of the molecular biol-
ogy age and the availability of more and more sequences, 
it became obvious, that differences within a given sero-
type exist for BoNT/A, B, E and F (Hill and Smith 2013). 
These so called subtypes can differ up to 36% on the 
amino acid level within a given serotype. So far, more 
than 40 subtypes have been described in the literature 
and even more subtypes are expected to be discovered 
in the future. Subtypes of a given serotype have been 
shown to differ in their biological activity, e.g. their kinet-
ics of substrate cleavage, affinity to receptors and overall 
activity (Henkel et al. 2009, Kalb et al. 2012b, Wang et al. 
2013b, Whitemarsh et al. 2013, Kull et al. 2015).
This high molecular variability poses a major challenge 
for the development of diagnostic assays covering all 
re levant sero- and subtypes (Dorner et al. 2013). 
Although a number of multiplexed detection methods 
targeting either the DNA (Lindström et al. 2001, De 
Medici et al. 2009, Fach et al. 2009, Kirchner et al. 2010, 
Fach et al. 2011, Fenicia et al. 2011, Anniballi et al. 2013a, 
Anniballi et al. 2013b, Woudstra et al. 2013) or the BoNT 
protein (Pauly et al. 2009, Zhang et al. 2012, Singh et al. 
2015, Hansbauer et al. 2016, Rosen et al. 2017b) have 
been described, false negative results due to the high 
variability affecting PCR and immunological methods 
alike have been reported (Gibson et al. 1987, Fach et al. 
1996, De Medici et al. 2009, Mad’arova et al. 2017). A fea-
sible way to reduce this molecular complexity introduced 
by the different BoNT subtypes is the detection of either 
their full mode of action or parts of it. The rationale here 
lies within the consideration that point mutations that 
cause the failure of DNA- or protein-based assays might 
not necessarily impair functional detection as long as 
TABLE 1: Different requirements for an animal replacement 
method for pharmaceutical potency testing as compared to dia-
gnostic assays for botulism





Reliable detection of all 
>40 pathogenic sero- and 
subtypes
Detection of predefined 
sero- and subtypes known 
by production process, only 
BoNT/A1 and B1
Sample matrix Detection from complex 
matrices: clinical, food and 
environmental matrices 
Detection from physiological 
solutions, matrix not critical
Time to results Critical due to time frame for 
therapeutic intervention
Not critical: dictated by 
length of production process
Precision Approximate range of activity 
sufficient
Precise quantification of 
biological activity crucial
Mode of action Positive detection more 
important than coverage of 
complete mode of action
Coverage of complete mode 
of action (binding, translo-
cation, cleavage) crucial for 
reliable quantification of 
potency
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Second, botulism diagnostics is always performed from 
complex sample matrices. Those could either be clinical 
sample materials such as sera, feces, organ extracts; com-
plex food samples such as meat, fish or pickled vegeta-
bles; environmental matrices such as wipe samples, soil, 
or dust and finally cell culture supernatants from bacte-
rial enrichment cultures (Dorner et al. 2013). Testing of 
BoNT production from food matrices also plays a role for 
food safety studies performed in the food industry, e.g. 
for testing of different storage conditions after artificial 
spiking of food with Clostridial spores. Here, similar 
challenges apply with respect to matrix interference and 
toxin recovery as for diagnostics of food samples in case 
of outbreak analysis, with the important difference that 
for food safety studies the BoNT serotype is known prior 
to analysis (Peck 2006). The analysis of complex matrices 
implies that the assays have to be robust and/or contain 
an enrichment step for extracting the toxins from the 
matrix. Additionally, the analytical procedure has to take 
into account that the toxin has to be detected in dif-
ferent molecular forms from different matrices. In food 
matrices and bacterial culture supernatants, the toxin is 
usually present in its complexed form. While the com-
plex is stable at acidic pH, it dissociates spontaneously 
at physiological pH and high ionic strength (Sakaguchi 
1982, Simpson 2004, Dorner et al. 2013) – this is of 
relevance for the analysis of different food samples. In 
serum, however, free BoNT is found and the exact fate of 
the associated complex proteins is not yet clear to date. 
Any diagnostic procedure has to ensure that both the 
free BoNT and the toxin in its complexed form can be 
detected from complex matrices. Contrary, BoNT phar-
maceuticals are highly purified toxin preparations (either 
in its free or complexed form) in physiological buffer 
containing additives such as human serum albumin or 
stabilizers. Therefore, for testing BoNT pharmaceuti-
cals the matrix does not pose an analytical challenge, 
although there has been a report on an unusual enzy-
matic activity of human serum albumin contained as a 
stabilizer (Jones et al. 2011).
Third, due to the short time frame during which 
administration of neutralizing antitoxins is effective, the 
time to results is highly relevant for botulism diagnostics 
(Tacket et al. 1984). Contrary, the time frame for potency 
testing is dictated by the much longer production pro-
cess of the pharmaceutical formulations and is hence 
not critical.
Forth, there are high demands on the precision of 
assays for potency testing where exact dosing requires 
highly accurate, reproducible and quantitative results. 
On the contrary, the order of magnitude of the biological 
activity is usually sufficient for diagnostics.
Finally, there is a broad agreement that in order to 
accurately quantify the potency of BoNTs in pharma-
ceutical preparations, all steps critical in vivo to fulfill the 
complete mode of action have to be depicted (Adler et 
al. 2010). For botulism diagnostics the main issues are 
confident results and coverage of all sero- and subtypes 
from matrices without risking false negatives. 
The mouse bioassay
Already in the 1920s, the mouse bioassay (MBA) was 
proposed for toxin detection and determination of its 
activity (Bengtson 1921). Until now it is still the most 
widely used “gold standard assay” to determine the 
potency of highly pure BoNT pharmaceuticals and to 
detect toxin from suspect samples of botulism (Dorner 
et al. 2013, Worbs et al. 2015). By way of example, for 
diagnostics of veterinary botulism a recent survey among 
11 Western European countries, among them Germany, 
revealed that 81% of veterinary laboratories still apply 
the MBA for sample testing (Skarin et al. 2013). In fact, 
in Germany the only approved standard DIN 10102 on 
“microbiological analysis of meat and meat products and 
detection of C. botulinum and BoNT” relies on the MBA. 
In the absence of any alternatively accepted method, 
this procedure is also used for clinical specimens. Inter-
nationally, the AOAC Official Method 977.26 is the cor-
responding standard on “C. botulinum and its toxins in 
foods”, effective since 1977 (AOAC International 1977).
The MBA requires different dilutions of particle-free 
sample materials (e.g. sera, culture supernatants, food 
extracts) to be injected intraperitoneally into mice. Sub-
sequently the mice are monitored for typical botu-
lism symptoms such as ruffled fur, labored breathing, 
wasp-like abdomen due to increased respiratory efforts, 
weakness of limbs and, finally, total paralysis and death 
by respiratory failure (Lindström and Korkeala 2006, 
Dorner et al. 2013). The assay can take up to four days as 
at low doses the development of neurotoxic effects can 
be delayed. For confirmation of specificity and to deter-
mine the disease causing serotype, toxin neutralization 
by specific antisera has to be performed in connection 
with further tests for specificity and activity (heat inac-
tivation of the heat labile toxin; trypsin-activation for 
selected serotypes). Taking into account all assay controls 
suggested in DIN 10102, up to 44 mice are needed per 
single sample. Overall, conservative estimations indicate 
that in Germany between 8000 and 10,000 mice are 
needed each year for the purpose of BoNT diagnostics 
in all clinical and veterinary laboratories involved. This is 
remarkable in light of the low number of positive cases 
but reflects the high number of suspect cases which 
have to be analyzed to clarify the absence of botulism. 
For information, 10-20% of all suspect samples turn 
out to be positive in the German Consultant Labora-
tory for Neurotoxin-producing Clostridia at the Robert 
Koch Institute. This relatively high percentage of positive 
samples among all samples tested might reflect the fact 
that for suspect cases with initial positive results often 
numerous follow-up samples are analyzed of which 
several usually turn out to be positive (epidemiological 
investigation to identify the source of an outbreak). Even 
larger numbers of animals are needed for the potency 
testing of BoNT pharmaceuticals: Here, the European 
Pharmacopoeia mandates the LD50 test in mice, which 
precisely measures the toxin’s dose lethal for half of the 
animals injected (European Pharmacopoeia Commis-
sion 2005, European Pharmacopoeia Commission 2011). 
For potency testing, it is estimated that in 2010, at least 
600,000 mice were used worldwide for potency testing 
of BoNT/A pharmaceuticals (Bitz 2010). In Germany, 
only in 2014 approximately 60,000 and 90,000 mice 
were used for potency testing of pharmaceutical BoNT/B 
and BoNT/A preparations, respectively (German Federal 
Institute for Risk Assessment 2016, Wild et al. 2016).
Considering this high number of animals needed for 
potency testing and diagnostics, why is the MBA still in 
use to date? First, with an exquisite detection limit in the 
low pg per mL range, the assay offers the high sensitivity 
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necessary for both potency testing as well as detection of 
traces of the toxin from clinical, food and environmental 
samples for botulism diagnostics (Dorner et al. 2013). 
Second, the assay covers the complete mode of action 
of all functional domains of the neurotoxin hereby truly 
reflecting the activity of the molecule, a fact especially 
important for potency testing. Third, the MBA can detect 
all toxic sero- and subtypes (including any yet unknown 
subtypes) from complex matrices, which is crucial for 
diagnostic settings. Finally, it is technically straightfor-
ward to perform as it involves only basic sample prepa-
ration steps and injections into mice. 
However, the mouse bioassay also has some grave dis-
advantages for both technical and ethical reasons. Gener-
ally, the MBA as an in vivo assay is very difficult to stand-
ardize due to the current absence of certified reference 
materials (Sesardic et al. 2003, Lindström and Korkeala 
2006). Along this line, inter-laboratory comparisons have 
shown that MBA results may be variable depending on 
the age and strain of mice used and other experimental 
factors (McLellan et al. 1996, Sesardic et al. 2003). Indeed, 
in terms of quantitation of BoNT activity, the MBA has 
recently been shown to be more variable than other 
assays directly investigated in parallel in an international 
proficiency test (Worbs et al. 2015). Additionally, the need 
for an animal facility as well as trained and approved per-
sonnel significantly adds to the overall cost of the MBA 
and confines the circle of potential users to appropriately 
equipped laboratories. Furthermore, the long duration of 
up to four days can be critical, especially in a diagnostic 
setting. Here, a rapid laboratory confirmation of the clini-
cal diagnosis allows for a timely administration of BoNT-
neutralizing antisera – still a frequently used treatment 
option which is effective only during the early stages of 
the intoxication as long as as long as toxins are still circu-
lating in the bloodstream (Kodihalli et al. 2017).
Besides that, species differences between mice and 
humans can lead to misinterpretation of results, as dem-
onstrated for BoNT/B which is 40 times more potent in 
mice due to a single amino acid difference located in the 
protein receptor binding site (Peng et al. 2012, Strotmeier 
et al. 2012). Similarly, BoNT/D is functionally active in 
mice, but does obviously not affect humans (Coffield et 
al. 1997). Additionally, unspecific toxicity caused by other 
sample components can also lead to misinterpretation 
of results (Segner and Schmidt 1968, Solberg et al. 1985, 
Dezfulian 1989, Government Inquiry into the Whey 
Protein Concentrate Contamination Incident 2014). This 
is also the reason why toxin neutralization assays are 
routinely performed which further add to the timeframe 
required to perform the MBA.
Most importantly, however, in light of the high num-
ber of mice consumed and their high level of distress, 
there is ethical controversy about the employment of 
the MBA. This mostly affects its application for potency 
testing while its application in diagnostics is considered 
as ethically justifiable in the current absence of adequate 
internationally accepted alternative methods. Along this 
line, the effective Directive 2010/63/EU of the European 
Parliament on the protection of animals used for scien-
tific purposes stipulates in Article 4 the strict adherence 
to the Russel’s and Burch’s 3R principles, reduction, 
refinement and replacement of animals, wherever pos-
sible (Russell and Burch 1959, The European Parliament 
and the Council of the European Union 2010). The 
Directive also prescribes the avoidance of death as an 
end-point to prevent severe suffering of animals. Wher-
ever possible, it should be substituted by more humane 
end-points such as specific clinical signs and symptoms.
In this context, several assays have been established to 
fulfill Russel’s and Burch’s 3R principles for the potency 
testing of pharmaceutical BoNT preparations containing 
BoNT/A1 or BoNT/B1 (Sesardic and Gaines Das 2008, 
Bitz 2010). Of those, as humane endpoint of the MBA the 
measurement of local paralysis has been introduced as 
a refinement method (Sesardic et al. 1996, Wilder-Kofie 
et al. 2011, Broide et al. 2013, Cevc 2015). These assays 
measure e.g. flaccid paralysis (Sesardic et al. 1996, Jones 
et al. 2006), abdominal ptosis (Takahashi et al. 1990), 
hind limb paralysis (Sugiyama et al. 1975, Pearce et al. 
1994, Aoki 2001), grip strength (Meyer et al. 1979, Torii 
et al. 2011), toe-spread reflex (Wilder-Kofie et al. 2011), 
rotarod (Pellett et al. 2015b), and running wheel assays 
(Kutschenko et al. 2011). These assays can be sublethal 
with known amounts of toxin applied, still they repre-
sent animal experiments, require several days to per-
form and are in vivo tests with a more or less subjective 
readout. Alternatively, an ex vivo replacement method 
measuring paralysis of an explanted hemidiaphragm has 
been developed (Rasetti-Escargueil et al. 2009, Bigalke 
and Rummel 2015). This mouse hemidiaphragm assay 
still relies on animals which are, however, sacrificed 
humanely. In essence, the assay employs the isolated N. 
phrenicus-hemidiaphragm tissue in an organ bath which, 
by incubation with BoNT undergoes a dose-dependent 
characteristic decrease of the contraction amplitude of 
the indirectly stimulated muscle. The assay can be well 
standardized and was shown to deliver superior quali-
tative and quantitative results when directly compared 
to the MBA in a recent proficiency test (Worbs et al. 
2015). In the same proficiency test the hemidiaphragm 
assay also proved to be robust against matrix interfer-
ence – this, however, has to be taken with care, since a 
comprehensive panel of matrices has not yet been tested 
(Bigalke and Rummel 2015). The main limitations of this 
assay lie within the relatively high instrument costs, the 
technical expertise needed to perform the assay repro-
ducibly and the low throughput format. 
Replacement methods for potency  
testing
In order to overcome the limitations of the MBA, inten-
sive efforts have been put into the development of 
alternative replacement methods for potency testing of 
highly pure BoNT pharmaceuticals (Straughan 2006). 
In the last decade, significant progress has been made 
in this field worldwide by establishing cell-based assays 
which do not depend on animals any more. Cell-based 
assays employ cell lines which are sensitive for BoNT/
A1 or B1 and measure the binding, uptake, translocation 
and intracellular substrate cleavage of the neurotoxins by 
different read-outs. They offer the advantage of covering 
the complete mode of action needed for a full replace-
ment of potency testing (Pellett 2013).
Cell-based assays
In principle, cells from different sources can be employed 
for potency testing of BoNTs. Besides primary neuronal 
cells isolated from different sources, continuous cell 
lines and stem cell derived cells have all been evalu-
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ated for detection of BoNTs with different challenges 
involved. Primary cells usually show high sensitivity 
towards BoNTs but still require the sacrifice of animals 
and prolonged cultivation by a skilled experimenter. 
Continuous cell lines derived from cancer cells, e.g. 
PC12, Neuro-2a or P19 cells, are easier to obtain and 
cultivate. The challenge here lies within the limited 
sensitivity of many cell lines, possibly due to different 
degrees of differentiation from a cancerous background 
as well as differential expression of receptor or substrate 
molecules compared to primary neuronal cells (Yowler 
et al. 2002, Dong et al. 2008, Tsukamoto et al. 2012, Pel-
lett 2013, Rust et al. 2017). However, if suitable cell lines 
are identified, high sensitivity can be reached as exem-
plified by the first FDA approved replacement assay for 
the MBA which is based on a highly susceptible SiMa 
cell line (Fernández-Salas et al. 2012). Finally, stem 
cell-based cell lines offer a sensitive and well defined 
alternative to cancer derived cell lines (Whitemarsh 
et al. 2012, Pellett et al. 2015a). Additionally, human 
derived stem cells circumvent potential species specific 
differences in potency as has been observed for BoNT/B 
(Strotmeier et al. 2012). Those cell lines can be pur-
chased cryopreserved from commercial suppliers and 
subsequently require only plating and relatively short 
cultivation before use. Hereby, despite initially higher 
costs the overall costs might be comparable to the culti-
vation of continuous cell lines including associated costs 
for quality control tests and personnel. Induced pluripo-
tent human stem cells have also been implemented in 
the second approved replacement assay for the potency 
determination (Eisele and Mander 2015). This assay is 
based on commercially available hiPS stem cells which 
have been described before (Whitemarsh et al. 2012) 
and are cultivated under addition of GT1b to reduce 
variability and to increase sensitivity. 
An important parameter to differentiate cell-based 
assays is the readout which is employed to quantify the 
action of BoNTs in the cells. Most often, cleavage of sub-
strate proteins as the final step of intoxication is moni-
tored. This can either be done directly using Western 
blotting or by cleavage-specific, so called neo-epitope 
specific antibodies. By definition, neo-epitope specific 
antibodies detect only the cleaved, but not uncleaved 
substrate (Bak et al. 2017, Pellett et al. 2017) (Fig. 3A). 
These assays can provide sensitive detection, especially 
if high affinity neo-epitope specific antibodies are imple-
mented in an ELISA-based approach. This has the addi-
tional advantage to allow a high throughput (Fernán-
dez-Salas et al. 2012, Pellett et al. 2017). Alternative 
readouts based on fluorescence or luminescence and, 
more recently, electrochemical multi-electrode arrays 
have also been introduced (Dong et al. 2004, McNutt et 
al. 2011, Jenkinson et al. 2017).
Along these lines, a luminescence-based cell line 
with a novel readout has been developed (Pathe-
Neuschafer-Rube et al. 2015). In this work, a SiMa cell 
line expressing a pH-stable firefly-luciferase, which 
was sorted into secretory vesicles by the inclusion 
of an N-terminal sorting sequence, was shown to 
enable sensitive inhibition of luciferase secretion into 
the supernatant after incubation with BoNT/A. Such 
an approach does circumvent the need for detection of 
the cleaved substrate by serotype-specific neo-epitope 
antibodies by directly measuring the inhibition of neu-
rotransmitter release. Hereby the applicability of this 
cell line is theoretically broadened for the second 
therapeutically relevant serotype BoNT/B. However, 
this is currently not yet feasible without further assay 
modification, since the respective SiMa cell line used 
is not susceptible to BoNT/B due to the absence of the 
specific substrate VAMP-2. Further work would also be 
FIGURE 3: A. Different readouts 
employed in assays based on enzymatic 
cleavage of substrate proteins. Short 
peptide substrates are detected by mass 
spectrometry in the so called Endopep-
MS approach, while FRET or lumine-
scence-based assays measure the change 
in fluorescence intensity after cleavage. 
Last, detection of cleaved substrate can 
also be based on neo-epitope specific 
antibodies which specifically bind to 
cleaved, but not uncleaved substrates 
on the newly exposed cleavage sites.  
B. Advantages and disadvantages of  
the different approaches. 
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needed to increase the sensitivity and reduce the vari-
ability of this promising approach.
The lack of VAMP-2 expression was a general obsta-
cle standing in the way of full replacement of the MBA 
for potency testing for the detection of BoNT serotype 
B. Very recently, this could be overcome by an elegant 
approach by Rust and colleagues (Rust et al. 2017). 
In their work, they also employed the SiMa cell line 
which was used in the FDA approved replacement 
assay for BoNT/A (Fernández-Salas et al. 2012). The 
authors rendered the SiMa cell line susceptible to sub-
strate cleavage by BoNT/B by introducing the VAMP-2 
substrate. By generating a luciferase-VAMP-2 fusion 
protein they were able to capture cleaved VAMP-2 using 
a neo-epitope specific antibody and detect the captured 
molecule in a highly sensitive one-step ELISA via the 
luciferase activity. A remaining limitation was the usage 
of a polyclonal neo-epitope specific antibody that might 
be prone to lot-to-lot variations hereby complicating a 
comprehensive assay validation.
Finally, in a proof-of-principle study, the applicability 
of mouse embryonic stem cells grown on multi-electrode 
arrays to monitor the mode of action of BoNT/A by meas-
uring the inhibition of electrochemical burst was shown 
in an interesting study (Jenkinson et al. 2017). An earlier 
study had already shown that mouse embryonic stem 
cells and an electrochemical readout of bursts by patch-
clamp technique could be used for sensitive detection of 
BoNT/A, BoNT/B and tetanus toxin (Beske et al. 2015, 
Beske et al. 2016). Advancing the previous approach, 
Jenkinson et al. (2017) employed a multi-electrode array 
to record the neuronal network activity, hereby simplify-
ing the experimental procedure. Although promising, it 
remains to be determined whether these rather sophis-
ticated approaches offer true advantages over the tech-
nically simpler and broader applicable cell-based assays 
employing validated ELISA-based read-outs (Pellett et 
al. 2017, Yadirgi et al. 2017).
Binding and cleavage-based assays
Despite offering the only non-animal approach cover-
ing the complete mode of action consisting of binding, 
uptake, translocation, and intracellular substrate cleav-
age, cell-based assays also have technical limitations. 
These include long cultivation times ranging from few 
days to weeks to establish neuronal cell lines, a substan-
tial level of expertise needed and significant assay costs 
associated especially with stem cell-based approaches, 
and a long incubation time for cleavage which is required 
to reach sensitive detection (Pathe-Neuschafer-Rube et 
al. 2015, Jenkinson et al. 2017). Consequently, simpler 
and more robust assays covering parts of the neurotox-
ins’ mode of action, namely receptor binding and cleav-
age, have been developed. Although not appropriate for 
a complete replacement, such assays could potentially 
contribute to reducing the overall number of animals 
needed for potency determination of BoNT pharmaceu-
ticals by replacing the MBA during individual production 
steps.
The concept of combining receptor binding and sub-
strate cleavage was introduced by binding of BoNT/A, B, 
and F to synaptosomes, which represent isolated syn-
aptic terminals from neurons and are prepared from rat 
brains, followed by subsequent cleavage of biotinylated 
substrate molecules SNAP-25 or VAMP1. Cleaved sub-
strates were detected by polyclonal neo-epitope spe-
cific antibodies in an ELISA-based format (Evans et al. 
2009). While testing both receptor-binding and enzy-
matic cleavage this assay has the disadvantage of relying 
on synptosomes from rat brains which are tedious to 
purify, not well defined and still require animals as organ 
donors. A more straightforward approach to detect cor-
rectly folded BoNT/A containing both the heavy- and 
light chain connected by the disulfide bond relied on 
dual-coated ELISA plates. Here, both a monoclonal anti-
body targeting the heavy chain and SNAP-25 as target 
of the enzymatically active light chain were immobilized 
to the microplates (Liu et al. 2012). However, good cor-
relation with the biological activity as determined by 
the MBA required incubation with a chaotropic agent. 
This was done to prevent binding of partially denatured 
BoNT/A as both an endopeptidase assay as well as 
an ELISA based capture approach both overestimated 
the relative potency due to also measuring (partially) 
denatured BoNT molecules. Nevertheless, this assay was 
shown to be suitable for detection of BoNT/A from clini-
cal and environmental food samples making it an inter-
esting tool for botulism diagnostics (Jones and Marks 
2013). However, as a monoclonal antibody was used for 
the binding step, this assay tested the enzymatic activity 
in combination with the presence of a disulfide-bonded 
heavy chain, but explicitly not the functional receptor 
binding.
The latter issue was pursued in another work where 
binding to the isolated protein receptor of BoNT/A, 
SV2C, was assayed in conjunction with detection of the 
enzymatic light chain activity by a recombinant com-
mercially available SNAP-25 Förster resonance energy 
transfer (FRET) substrate (Gregory et al. 2014). FRET 
substrates are short peptides flanked by a donor and 
an acceptor fluorophore and can be used to monitor 
the cleavage of the synaptic substrates (Fig. 3). Here, a 
change in fluorescence upon incubation with a BoNT 
containing sample indicates cleavage activity. In the 
work by Gregory and colleagues, the assay turned out 
to be only moderately sensitive, despite a reasonable 
correlation with the MBA. This limited sensitivity was 
most probably caused by the incomplete presentation of 
the receptor complex as neither the dual-receptor bind-
ing was implemented (the addition of the ganglioside 
GT1b did not show improved sensitivity), nor the crucial 
N-glycan structure on the SV2C receptor was present 
which was recently shown to mediate high-affinity bind-
ing and toxicity of BoNT/A (Mahrhold et al. 2016, Yao et 
al. 2016).
Similarly, a bifunctional assay testing binding to a 
short peptide comprising the crucial amino acids in 
Syt for BoNT/B receptor recognition and cleavage of a 
VAMP-peptide to quantify BoNT/B neutralizing anti-
bodies employed the protein receptor only (Rosen et al. 
2016); again, this approach failed to mediate the high 
affinity dual-receptor binding (Weisemann et al. 2016, 
Desplantes et al. 2017). Finally, highly sensitive detec-
tion of the receptor binding and substrate cleavage of 
BoNT/B was achieved in a so called BINACLE assay 
(binding and cleavage assay) (Wild et al. 2016). Here, 
the dual-receptor binding was experimentally achieved 
by coating both ganglioside and the protein receptor 
Syt onto ELISA plates, before the cleavage of VAMP was 
detected by a cleavage specific polyclonal neo-epitope 
specific antibody. This assay seems to be a technically 
straightforward and highly sensitive approach, yet cor-
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relation with the MBA and thorough validation studies 
will have to be performed in the future.
In conclusion, while cell-based assays offer the oppor-
tunity to fully replace the MBA for potency testing due 
to the depiction of the complete mode of action, bind-
ing and cleavage assays can contribute to reduce the 
overall number of animals used. Notably, the latter type 
of assays could also be implemented for diagnostics of 
botulism as they potentially overcome several of the 
challenges observed here.
Replacement methods for diagnostics 
of botulism
Most developments towards animal replacement meth-
ods have been focused on the potency testing of phar-
maceutical BoNT preparations. This work has led to two 
FDA approved assays so far (Fernández-Salas et al. 2012, 
Merz Pharma GmbH & Co. KGaA 2015). Independ-
ent of these efforts, replacement methods for botulism 
diagnostics are also needed, but are less often addressed 
(Lindström and Korkeala 2006, Cai et al. 2007). Impor-
tantly, separate developments are needed in this field 
which take into account the fundamentally different 
requirements of diagnostic approaches as compared to 
potency testing (Tab. 1 and section on “Challenges in 
BoNT detection” (Straughan 2006)).
It is those prerequisites that have been dictating the 
different setups of animal replacement methods devel-
oped for either diagnostics or potency testing in the 
past. The requirement to depict the complete mode of 
action has pushed replacement assays for potency test-
ing strongly towards cell-based assays (Pellett 2013). 
However, those assays are not well suited for the detec-
tion of BoNT from complex sample materials which is 
needed for diagnostics due to the potential interference 
of matrix components with cell viability and the need for 
sterile samples. Instead, in the field of diagnostics reduc-
ing the risk of false negative results paired with the high 
sensitivity of enzymatic assays has favored assays which 
detect the enzymatic activity of the BoNTs. Most critical, 
enrichment and purification steps have to precede such 
assays to remove unspecific proteases found in complex 
matrices (Jones et al. 2009) as well as to provide opti-
mum buffer conditions for the in vitro cleavage reaction 
(Jones et al. 2008).
Enrichment to enable detection from complex  
matrices
Usually, in diagnostic settings antibodies coupled to 
magnetic beads are used for toxin enrichment from 
complex matrices (Dunning et al. 2012, Kalb et al. 2015c, 
Hansbauer et al. 2016). Hereby, enrichment from larger 
sample volumes enable sensitive detection while the 
optimization of washing steps and cleavage buffers ena-
ble the efficient removal of both inhibiting substances 
and unspecific proteases (Kalb et al. 2006).
Generally, there are some caveats that have to be 
considered when choosing antibodies for enrichment 
of BoNTs. Besides standard requirements such as high 
affinity and detection of native toxins from solution 
(Stern et al. 2016a, Stern et al. 2016b), great care has 
to be taken when choosing the antibodies’ binding site 
on the toxins. Mostly, antibodies targeting the recep-
tor binding domain are better suited as enrichment 
antibodies as they do not interfere with the subse-
quent enzymatic cleavage of the light chain (Kalb et 
al. 2009). However, there are notable examples where 
antibodies also targeting the light chain can lead to high 
sensitivity (Bagramyan et al. 2008). Therefore, for every 
experimental approach, an optimally matching antibody 
has to be selected for toxin extraction – there is no “one-
for-all-purposes” antibody, and results obtained in one 
experimental setting cannot necessarily be transferred to 
a different experimental setup. 
Additionally, it is highly crucial to select an antibody 
which is able to detect all relevant BoNT subtypes of a 
given serotype (see section “Challenges in BoNT detec-
tion”) – a lack in binding to individual subtypes of a 
serotype would render the assay false negative. One 
possibility to circumvent this challenge is to implement 
pan-specific antibodies binding to conserved epitopes 
(Kalb et al. 2010) or to implement oligoclonal mixtures 
of antibodies complementing each other’s sub- and 
serotype binding profiles.
Overall, high affinity monoclonal antibodies are bet-
ter suited for extraction purposes compared to poly-
clonal antibodies, since their potential cross-reactivity 
with matrix components is usually limited and/or can 
be better controlled for. However, a current limitation 
in the field is that those high quality reagents are not 
commercially available and are restricted to few expert 
laboratories worldwide (Dorner et al. 2016). Along 
the same line, the testing of antibody specificity for 
binding of the known subtypes of the BoNT serotypes 
has been hampered by the fact that there is no single 
laboratory worldwide which has access to all relevant 
subtypes.
An alternative approach for toxin enrichment would 
lie within the coupling of the high-affinity endogenous 
receptors instead of antibodies to magnetic beads. How-
ever, this is not a trivial approach, since the BoNTs 
bind to two receptors of different molecular nature 
(transmembrane protein receptors, gangliosides, Fig. 2). 
Notably, very recent data indicate that BoNT/B, DC and 
G employ even ternary interactions – instead of dual 
interactions as previously anticipated – with a protein, 
ganglioside, and lipids (Stern et al. 2018). Additionally, at 
least for selected BoNTs, here BoNT/A, a highly specific 
post-translational modification of the protein receptor 
has been identified to be crucial for high-affinity binding 
(Yao et al. 2016). Furthermore, the individual subtypes 
of a given serotype can differ in their receptor binding 
affinities (Whitemarsh et al. 2013, Benoit et al. 2017, 
Davies et al. 2017) and as such have intrinsic difficulties 
similar to monoclonal antibodies. Regardless, subtypes 
with a lower affinity towards their receptors should also 
be less toxic in vivo so that a receptor-based enrichment 
step would give results more comparable to the MBA. 
In this context, novel technical approaches are needed 
to implement the dual-receptor binding concept appro-
priately.
Cleavage-based assays for sensitive detection
Cleavage-based assays suitable for diagnostic purposes 
as potential replacement methods for the MBA can be 
categorized by the different readouts used to detect the 
cleaved synaptic substrates (Fig. 3). While all assays can 
be used to detect the enzymatic activity of BoNTs, they 
are associated with different advantages and disadvan-
tages, which are summarized below.
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Mass spectrometry-based detection of BoNT activity by 
Endopep-MS
The mass spectrometry (MS)-based endopeptidase 
activity assay (Endopep-MS) is a functional method for 
rapid and sensitive detection, differentiation and quan-
tification of all known BoNT serotypes (Barr et al. 2005, 
Boyer et al. 2005). The method combines the serotype-
specific cleavage of a peptide substrate derived from the 
toxins' natural target in the SNARE complex with the 
highly sensitive, accurate detection and identification of 
the resulting two cleavage products by MS (Fig. 3). Either 
high-resolution matrix-assisted laser desorption/ioniza-
tion time-of flight (MALDI-TOF) MS or liquid chro-
matography (LC) electrospray ionization (ESI) tandem 
MS (MS/MS) can be used to depict the two cleavage 
products of known mass. Serotypes BoNT/A, C and E 
can be distinguished by unique cleavage sites in SNAP-
25, whereas BoNT/B, D, F, G and HA target VAMP-2 at 
specific amino acid positions (Fig. 2). Due to the fact 
that functional assays are sensitive towards interfer-
ing substances, e.g. endogenous proteases in stool, the 
method needs an immunoaffinity enrichment step prior 
to the cleavage reaction, combined with a high salt 
washing step to remove matrix components (Wang et al. 
2011). The enrichment by serotype specific monoclonal 
antibodies coupled to magnetic beads (Kalb et al. 2006, 
Gaunt et al. 2007, Kalb et al. 2008, Kalb et al. 2009, Kalb 
et al. 2011b, Parks et al. 2011, Wang et al. 2011) made 
the Endopep-MS assay highly suitable for the detection 
of active BoNT from complex matrices like serum (Kalb 
et al. 2006, Parks et al. 2011), stool (Kalb et al. 2006), 
foods (Kalb et al. 2015a) and bacterial culture superna-
tants (Kalb et al. 2008, Wang et al. 2014) with limits of 
detection in the range of the MBA or below. Technical 
improvements comprised enhancing peptide substrate 
stability, reducing possible unspecific cleavage by endog-
enous proteases, and increasing the detection sensitivity 
by using artificial, optimized substrates to deliver limits 
of detection for BoNT/A at 0.1 mouse LD50/mL (Wang 
et al. 2013a, Rosen et al. 2017a, Rosen et al. 2017b, Wang 
et al. 2017), for BoNT/B below 1 mouse LD50/mL (Rosen 
et al. 2015, Rosen et al. 2017b), for BoNT/C at 0.5 mouse 
LD50/mL (Wang et al. 2015a), for BoNT/E at 0.1 mouse 
LD50/mL (Rosen et al. 2014, Wang et al. 2015b, Rosen et 
al. 2017b) and for BoNT/F at 0.1 mouse LD50/mL (Kalb 
et al. 2011a).
Using different high quality antibodies for extraction, it 
was shown that the Endopep-MS assay can also detect 
veterinary BoNTs (Hedeland et al. 2011, Moura et al. 
2011, Björnstad et al. 2014, Wang et al. 2015a, Hansbauer 
et al. 2016). The method was even able to differentiate 
the highly related veterinary BoNT serotypes C and D 
and their mosaic variants CD and DC (Björnstad et al. 
2014, Hansbauer et al. 2016) by combining highly spe-
cific monoclonal antibodies targeting toxin subdomains 
plus appropriate cleavage conditions.
While the Endopep-MS assay was first introduced as a 
qualitative assay, it has been developed into a quantitative 
approach: For quantitative BoNT determination a known 
quantity of a stable isotope-labelled product peptide is 
added to the sample prior to analysis which can be differ-
entiated from the cleavage reaction product by its slightly 
different mass. For quantitation, the peak area derived 
from the isotope-labelled product peptide is compared to a 
standard curve of known BoNT concentrations in the 
matrix (Kalb and Barr 2013, Björnstad et al. 2014, Wang 
et al. 2014, Kalb et al. 2015a, Kull et al. 2015). The method 
delivered excellent results in terms of qualitative and 
quantitative detection of known BoNTs in a recent inter-
national proficiency test. In fact, in this exercise it was 
among the three animal replacement methods giving 
superior results than the MBA (Kalb et al. 2015a, Weise-
mann et al. 2015, Worbs et al. 2015, Dorner et al. 2016).
Compared to the MBA the Endopep-MS assay is 
more rapid (6 hours instead of 1–4 days) and of similar 
sensitivity. A further benefit is that BoNT enriched by 
antibodies can be introduced into an MS-based identifi-
cation and toxin subtyping procedure by high-resolution 
MS/MS amino acid sequencing (Kalb et al. 2012a, Kalb 
et al. 2015a, Hansbauer et al. 2016).
Independent of its application for diagnostics, the Endo-
pep-MS assay turned out to be instrumental in identify-
ing new BoNT sero- and subtypes by its ability to define 
new and unique cleavage sites in the SNARE substrates. 
This has been first shown for subtype BoNT/F5 (Kalb et 
al. 2012b) and confirmed for the newly identified BoNT/
FA (HA) (Kalb et al. 2015b). However, conclusions about 
neurotoxicity cannot be drawn based on Endopep-MS 
data alone as only the enzymatic activity is depicted. 
Therefore, cell based assays or MBA have to complement 
the Endopep-MS assay for an in depth assessment of the 
toxic potential of new BoNT sero- or subtypes (Zornetta 
et al. 2016, Zhang et al. 2017, Zhang et al. 2018).
Up to now, the Endopep-MS assay was limited to 
expert laboratories with access to expensive high-resolu-
tion mass spectrometers and specialized technical exper-
tise, but with rising interest for routine identification and 
typing of microorganisms by linear MALDI-TOFs cou-
pled with an automated analysis software (e.g. Bruker 
MALDI Biotyper®, bioMérieux VITEK® MS or Andromas 
SAS), more and more clinical and public health laborato-
ries use rapid and cost-effective mass spectrometers. In 
this context, it was recently shown that a Bruker MALDI 
Biotyper®, which is often available in modern clinical and 
public health laboratories, shows sufficient sensitivity 
and accuracy for BoNT detection by Endopep-MS assay 
(Perry et al. 2017).
Fluorescence or luminescence-based cleavage assays
For enzymatic detection of BoNT at lower instrumental 
levels than MS, fluorescence- or luminescence-based 
approaches have been developed. Here, peptide sub-
strates are labelled with a fluorescent or luminescent 
reporter molecule which is released upon substrate 
cleavage by BoNT. To this end, an assay detecting all 
BoNTs pathogenic to humans (BoNT/A, B, E, and F) was 
developed by immobilizing serotype specific peptides 
flanked with fluorescein and measuring the fluores-
cence intensity of supernatants after substrate cleavage 
(Schmidt et al. 2001). For assay automatization this 
principle has been transferred into a microfluidic format, 
allowing semiautomatic detection of BoNT/A (Frisk et 
al. 2009, Frisk et al. 2011). Similarly, bioluminescence 
has been employed to detect BoNT/E from buffer and 
BoNT/A from buffer as well as from different sample 
matrices (Stevens et al. 2013). Here, a recombinant 
substrate protein consisting of two consecutive SNAP-
25 sequences fused to luciferase was immobilized on 
magnetic beads. The release of luciferase after substrate 
cleavage and subsequent conversion of the luciferase 
substrate luciferin creates an amplified signal which 
could be monitored.
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Another approach employing fluorescence intensity 
as signal read-out for BoNT detection are FRET-based 
assays which are also in use for potency testing (see 
section “Binding and cleavage-based assays”, Fig. 3). 
The method is based on a substrate molecule equipped 
with a donor and an acceptor fluorophore. If donor and 
acceptor remain in close proximity, the fluorescence 
signal of the donor is quenched by the acceptor. Upon 
substrate cleavage by BoNT, donor and acceptor become 
separated which can be measured by an increase in flu-
orescence intensity as the donor is no longer quenched 
by the acceptor. Different variations of FRET-based 
assays for detection of BoNT/A and B have been devel-
oped. In respective assays, either commercially avail-
able peptide substrates were employed (Bagramyan et 
al. 2008, Rasooly and Do 2008, Rasooly et al. 2008) or 
– to push sensitivity – peptide substrates with special 
features such as the inclusion of important exosites 
or variations of donor and acceptor molecules were 
used (Anne et al. 2001, Dong et al. 2004, Pires-Alves 
et al. 2009, Poras et al. 2009). Akin to other enzymatic 
assays for BoNT detection, a stringent enrichment step 
was required to detect BoNT/A from complex matri-
ces. This was facilitated by immuno-enrichment using 
anti-BoNT/A antibodies coupled to magnetic (Rasooly 
and Do 2008, Rasooly et al. 2008) or sepharose beads 
(Bagramyan et al. 2008). Here, BoNT could be detected 
with high sensitivity from different matrices, including 
serum and different foods.
Advantages of fluorescence/luminescence-based 
approaches are their high sensitivity combined with a 
simple and fast assay protocol. Furthermore, commonly 
available laboratory equipment is sufficient to perform 
respective assays ensuring a broad applicability in routine 
laboratories. A major drawback is, however, that serotypes 
targeting the same substrate cannot be distinguished by 
the method, as all cleavage sites are within the donor 
and acceptor molecule on the same substrate (SNAP-25: 
A, C, and E; VAMP-2: B, D, F, G, HA). Shorter peptide 
substrates enabling a discrimination of serotypes E or 
A/C and B or F/D may be applied, but presumably would 
lead to a loss in sensitivity due to the lack of important 
exosites (Ouimet et al. 2013). Still, the discrimination 
of cleavage by BoNT/A and C or BoNT/F and D would 
hardly be possible without further substrate modifica-
tions, since their respective cleavage sites on SNAP-25 
or VAMP-2 are only one amino acid apart (Fig. 2).
Neo-epitope specific antibody-based assays
To develop simple assay systems detecting BoNT LC 
activity which can discriminate between the different 
BoNT serotypes, neo-epitope specific antibodies are 
employed. As already mentioned, these antibodies spe-
cifically recognize the newly exposed epitope on the 
cleaved substrate, while the intact substrate is not rec-
ognized. Regarding BoNT detection, such antibodies are 
employed to detect cleavage products of SNARE proteins 
after cleavage by the different BoNT serotypes (Fig. 3). 
Thus, different serotypes can be distinguished by detec-
tion of their specific cleavage site. Different approaches 
using different assay platforms – most of them employ-
ing polyclonal neo-epitope specific antibodies – have 
been developed for detection of BoNT/A, B, C, E, and F. 
Most commonly, neo-epitope specific antibodies were 
used in different variations of ELISA-based approaches. 
In a so-called Endopep-ELISA, the substrate molecule 
SNAP-25 or VAMP-2 is immobilized on microtiter plates 
and cleaved by addition of BoNT containing sample. 
The resulting neo-epitopes are then detected by neo-
epitope specific antibodies and an enzyme-conjugated 
anti-species antibody. Using this method, detection of 
BoNT/A, B, or C with sensitivities similar to the MBA was 
facilitated (Hallis et al. 1996, Jones et al. 2008, Jones et al. 
2009, Jones and Marks 2013). This approach was further 
extended by Liu et al. in a functional-dual-coating assay 
for BoNT/A detection (Liu et al. 2012): Here, in addi-
tion to SNAP-25, an anti-BoNT/A antibody was coated 
to accumulate the toxin on the microtiter plate surface 
achieving an excellent detection limit below the MBA. 
Detection of different toxin-contaminated foods was 
demonstrated for BoNT/B by employing immunoaffinity 
columns packed with a monoclonal anti-BoNT/B anti-
body for toxin enrichment. Subsequently, a biotinylated 
substrate was cleaved in solution and cleavage products 
were immobilized on streptavidin-coated plates and 
detected by neo-epitope specific antibodies (Wictome et 
al. 1999). Interestingly, an Endopep-ELISA format was 
among the three superior animal replacement methods 
in terms of qualitative and quantitative detection of 
BoNT in a recent international proficiency test (Simon et 
al. 2015, Worbs et al. 2015, Dorner et al. 2016).
In addition to Endopep-ELISA formats, an innova-
tive surface plasmon resonance (SPR)-based approach 
for the detection of BoNT/A, and E has been developed 
(Lévêque et al. 2013, Lévêque et al. 2014, Lévêque et 
al. 2015a, Lévêque et al. 2015b). Here, SNAP-25 was 
immobilized on the surface of a sensor chip. Then, BoNT 
containing samples were injected over the sensor surface 
and cleavage was monitored by injecting neo-epitope 
specific antibodies. In contrast to the ELISA-based 
methods mentioned above, the SPR sensor employed 
monoclonal neo-epitope specific antibodies for detec-
tion of cleavage products, thereby making it suitable for 
comprehensive validation studies and a wide applica-
tion. Impressive sensitivities greatly exceeding the MBA 
were achieved for detection from buffer as well as serum.
In summary, neo-epitope specific antibodies proved 
to be a highly suitable tool for detection of BoNT’s 
enzymatic activity in different assay platforms, deliver-
ing sensitivities below the MBA even in selected com-
plex matrices. Notably, cleavage activity for most BoNT 
serotypes (BoNT/B, C, F) on their respective substrates 
could be detected with polyclonal neo-epitope specific 
antibodies so far. Only for BoNT/A and E monoclo-
nal neo-epitope specific antibodies have been pub-
lished (Fernández-Salas et al. 2012, Lévêque et al. 2013, 
Lévêque et al. 2014, Lévêque et al. 2015b). Similar to pol-
yclonal anti-toxin antibodies used for enrichment strate-
gies, the use of polyclonal neo-epitope specific antibod-
ies is often hampered by their tendency to interfere with 
matrix components, limiting their broad applicability in 
a variety of complex matrices. Thus, the investigation of 
monoclonal neo-epitope specific antibodies for detec-
tion of all disease-causing serotypes is highly desirable 
in the future.
Remaining challenges and conclusions
The development of animal replacement methods for 
testing the presence and activity of BoNTs is a long 
pursued goal which mainly focused on replacement 
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methods for pharmaceutical potency testing. The efforts 
in this area have resulted in two FDA approved replace-
ment methods so far which are cell-based assays that 
depict the cellular uptake, translocation and substrate 
cleavage induced by BoNT/A1 (Fernández-Salas et al. 
2012, Eisele and Mander 2015, Merz Pharma GmbH & 
Co. KGaA 2015). Because of the exquisite specificity of 
BoNT for neuronal cells, the main challenge in develop-
ing assays for potency testing is to identify or to establish 
suitable cell lines which are equipped with the necessary 
receptors and endogenous substrate molecules to allow 
for a highly sensitive and reproducible activity determi-
nation comprising all steps of the toxin’s mode of action.
Due to fundamentally different requirements, the 
achievements in the field of potency testing cannot be 
transferred into the field of BoNT diagnostics. In the lat-
ter, detection of more than 40 different BoNT sero- and 
subtypes has to be achieved from complex clinical, food, 
and environmental matrices. To this end, several prom-
ising animal replacement methods have been devel-
oped depicting mostly the cleavage activity of BoNT 
either with or without demonstrating the presence of 
the receptor-binding domain. Several recent assays also 
explored the feasibility to display the binding of BoNT in 
vitro, followed by cleavage activity. This, however, turned 
out to be highly challenging due to the molecular struc-
ture of the BoNT receptors and their variability among 
serotypes – only the successful display of high-affinity 
binding would result in detection limits necessary to 
replace the MBA. Here, innovative approaches are nec-
essary to display the endogenous receptor molecules 
containing all necessary post-translational modifications 
in vitro. If solutions to this can be found, this would 
enable functional enrichment of BoNT via the receptor-
binding domain as described for binding and cleavage 
assays. However, before this can be a viable approach, 
further investigations of the precise molecular interac-
tion of all BoNT serotypes with their receptors have to 
be pursued, especially for serotypes other than BoNT/A 
and B taking into account the very recent findings of 
tripartite toxin-receptor interactions (Stern et al. 2018, 
Yao et al. 2016).
For the time being, the majority of diagnostic labo-
ratories use antibodies for enrichment of BoNTs from 
complex matrices. Here, the current limitation is that 
high affinity antibodies reactive against all subtypes 
of a given serotype are not commercially available and 
are restricted to few expert laboratories worldwide, if 
available at all (Dorner et al. 2016). Additionally, test-
ing of antibody specificity for binding of all known 
BoNT subtypes requires access to all relevant subtypes 
which is currently not possible. An international effort 
is needed to work on this issue, to make available high 
quality detection tools and BoNT subtypes to author-
ized laboratories in order to enable comprehensive 
validation studies. As a starting point, the European 
Commission has recently launched a research project 
called EuroBioTox under the Horizon 2020 program to 
network toxin laboratories and to support international 
validation of diagnostic approaches (The EuroBioTox 
Consortium 2017). For BoNT detection, a first step in 
the establishment of quality assurance schemes has 
been undertaken in a previous European program 
(The EQuATox Consortium 2012). In this framework, 
the first international proficiency test for the detection 
of BoNT/A, B and E from differently spiked matrices 
has been organized (Worbs et al. 2015, Dorner et al. 
2016). The exercise provided the valuable information 
that among several methods run in parallel on the 
same sample set, Endopep-MS and Endopep-ELISA 
approaches, which both do not require animals or 
animal tissues any more, delivered qualitative and/or 
quantitative results similar to or better than the MBA. 
Additionally, the mouse hemidiaphragm assay – still 
requiring animal tissue – delivered superior results. 
According to this information, those three functional 
approaches have the potential to significantly reduce 
the MBA for botulism diagnostics, provided that fur-
ther extensive validation studies will be performed in 
the future on a comprehensive set of clinical, food and 
environmental matrices. A complete replacement of 
the MBA might be hard to obtain because of its pivotal 
role in research but also for detection and characteriza-
tion of novel BoNT sero- and subtypes. Additionally, 
the MBA might still be needed as a supplementary 
or confirmatory assay to in vitro diagnostic assays 
and potency determinations. Further proficiency tests 
and method performance studies will be necessary to 
demonstrate the broad applicability, sensitivity, and 
robustness of the replacement methods under scru-
tiny. Finally, this work will be the basis for establishing 
internationally accepted recommended operating pro-
cedures to replace the current “gold standard” MBA, a 
process which requires further substantial work in the 
next decade.
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